Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2017 Nov 23

PMID 29164079

Citations 43

Authors

Martha Milade Torres Nupan

Alberto Velez Van Meerbeke

Claudia Alejandra Lopez Cabra

Paula Marcela Herrera Gomez

Affiliations

Soon will be listed here.

Abstract

Aim: The last systematic review of research on the behavior of children with neurofibromatosis type 1 (NF1) was in 2012. Since then, several important findings have been published. Therefore, the study aim was to synthesize recent relevant work related to this issue.

Method: We conducted a systematic review of the literature. Relevant articles were identified using the electronic databases PubMed, PsycINFO, and Scopus and a manual search of references lists. Thirty of 156 articles identified met the inclusion criteria. A quality evaluation of the articles was performed and the information was synthesized using a narrative approach.

Results: Compared with controls, children and adolescents with NF1 present significant alterations in language, reading, visuospatial skills, motor function, executive function, attention, behavior, emotion, and social skills. The prevalence of attention-deficit/hyperactivity disorder (ADHD) is important and can affect cognition and executive function variables. A high prevalence of autistic traits and autistic spectrum disorder were reported. The benefits of using statins to treat cognitive deficits are unclear. However, children with NF1 and ADHD seem to benefit from methylphenidate treatment. The presence of hyperintensities in brain magnetic resonance imaging data seem to be related to poor cognitive performance. Analysis of these lesions could help to predict cognitive alterations in children with NF1.

Interpretation: There has been important progress to evaluate cognitive characteristics of children with NF1 and to determine the physiological mechanisms of the concomitant disorders. However, discrepancies in relation to intelligence, learning disabilities, attention deficits, and treatment remain. Further investigations on this topic are recommended.

Citing Articles

Cognition and behavior in adults with neurofibromatosis type 1.

Bos-Roubos A, van Leeuwen H, Wingbermuhle E, van den Bosch L, Ossewaarde L, Taal W Front Neurol. 2024; 15:1476472.

PMID: 39677862 PMC: 11638057. DOI: 10.3389/fneur.2024.1476472.

Neurocognitive functioning in adults with neurofibromatosis type 1- a nationwide population-based study.

Doser K, Jepsen J, Kenborg L, Miskowiak K, Albieri V, Dalton S Orphanet J Rare Dis. 2024; 19(1):441.

PMID: 39609892 PMC: 11603635. DOI: 10.1186/s13023-024-03454-w.

[Progress and prospects in diagnosis and treatment of neurofibromatosis type 1].

Liu P Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024; 38(10):1166-1170.

PMID: 39433488 PMC: 11522528. DOI: 10.7507/1002-1892.202407005.

Autism Spectrum Disorder Symptom Profiles in Fragile X Syndrome, Angelman Syndrome, Tuberous Sclerosis Complex and Neurofibromatosis Type 1.

Lubbers K, Hiralal K, Dieleman G, Hagenaar D, Dierckx B, Legerstee J J Autism Dev Disord. 2024; .

PMID: 39395123 DOI: 10.1007/s10803-024-06557-2.

Lamotrigine for cognitive deficits associated with neurofibromatosis type 1: A phase II randomized placebo-controlled trial.

Ottenhoff M, Mous S, Castricum J, Rietman A, Oostenbrink R, van der Vaart T Dev Med Child Neurol. 2024; 67(4):537-549.

PMID: 39340758 PMC: 11875526. DOI: 10.1111/dmcn.16094.

References

DeBella K, Szudek J, Friedman J . Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000; 105(3 Pt 1):608-14. DOI: 10.1542/peds.105.3.608. View

Gilmore A, Milne R . Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf. 2001; 10(2):85-94. DOI: 10.1002/pds.564. View

Schachter H, Pham B, King J, Langford S, Moher D . How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2002; 165(11):1475-88. PMC: 81663. View

Hyman S, Gill D, Shores E, Steinberg A, Joy P, Gibikote S . Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology. 2003; 60(7):1139-45. DOI: 10.1212/01.wnl.0000055090.78351.c1. View

Feldmann R, Denecke J, Grenzebach M, Schuierer G, Weglage J . Neurofibromatosis type 1: motor and cognitive function and T2-weighted MRI hyperintensities. Neurology. 2003; 61(12):1725-8. DOI: 10.1212/01.wnl.0000098881.95854.5f. View

Lammert M, Friedman J, Kluwe L, Mautner V . Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005; 141(1):71-4. DOI: 10.1001/archderm.141.1.71. View

Hyman S, Shores A, North K . The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology. 2005; 65(7):1037-44. DOI: 10.1212/01.wnl.0000179303.72345.ce. View

Li W, Cui Y, Kushner S, Brown R, Jentsch J, Frankland P . The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol. 2005; 15(21):1961-7. DOI: 10.1016/j.cub.2005.09.043. View

Acosta M, Gioia G, Silva A . Neurofibromatosis type 1: new insights into neurocognitive issues. Curr Neurol Neurosci Rep. 2006; 6(2):136-43. DOI: 10.1007/s11910-996-0036-5. View

10.

Levine T, Materek A, Abel J, ODonnell M, Cutting L . Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol. 2006; 13(1):8-20. DOI: 10.1016/j.spen.2006.01.006. View

11.

Gill D, Hyman S, Steinberg A, North K . Age-related findings on MRI in neurofibromatosis type 1. Pediatr Radiol. 2006; 36(10):1048-56. DOI: 10.1007/s00247-006-0267-2. View

12.

Hyman S, Gill D, Shores E, Steinberg A, North K . T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry. 2007; 78(10):1088-91. PMC: 2117545. DOI: 10.1136/jnnp.2006.108134. View

13.

Watt S, Shores A, North K . An examination of lexical and sublexical reading skills in children with neurofibromatosis type 1. Child Neuropsychol. 2007; 14(5):401-18. DOI: 10.1080/09297040701595505. View

14.

Dennis M, Francis D, Cirino P, Schachar R, Barnes M, Fletcher J . Why IQ is not a covariate in cognitive studies of neurodevelopmental disorders. J Int Neuropsychol Soc. 2009; 15(3):331-43. PMC: 3075072. DOI: 10.1017/S1355617709090481. View

15.

Engert V, Pruessner J . Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Curr Neuropharmacol. 2009; 6(4):322-8. PMC: 2701285. DOI: 10.2174/157015908787386069. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

17.

Alivuotila L, Hakokari J, Visnapuu V, Korpijaakko-Huuhka A, Aaltonen O, Happonen R . Speech characteristics in neurofibromatosis type 1. Am J Med Genet A. 2009; 152A(1):42-51. DOI: 10.1002/ajmg.a.33178. View

18.

Evans D, Howard E, Giblin C, Clancy T, Spencer H, Huson S . Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010; 152A(2):327-32. DOI: 10.1002/ajmg.a.33139. View

19.

Chabernaud C, Sirinelli D, Barbier C, Cottier J, Sembely C, Giraudeau B . Thalamo-striatal T2-weighted hyperintensities (unidentified bright objects) correlate with cognitive impairments in neurofibromatosis type 1 during childhood. Dev Neuropsychol. 2010; 34(6):736-48. DOI: 10.1080/87565640903265137. View

20.

Huijbregts S, Swaab H, de Sonneville L . Cognitive and motor control in neurofibromatosis type I: influence of maturation and hyperactivity-inattention. Dev Neuropsychol. 2010; 35(6):737-51. DOI: 10.1080/87565641.2010.508670. View